Treatment of Nasopharyngeal Carcinoma with Epstein-Barr Virus-Specific T-Lymphocytes
|
|
- Julian Walton
- 5 years ago
- Views:
Transcription
1 Chapter 3 Chapter 3-57 Treatment of Nasopharyngeal Carcinoma with Epstein-Barr Virus-Specific T-Lymphocytes Karin CM Straathof, Catherine M Bollard, Uday Popat, M Helen Huls, Teresita Lopez, M Craig Morriss, Mary V Gresik, Adrian P Gee, Heidi V Russell, Malcolm K Brenner, Cliona M Rooney and Helen E Heslop Center for Cell and Gene Therapy, Departments of Pediatrics, Radiology, Pathology, and Medicine, Molecular Virology and Microbiology, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston TX 77030, USA. Blood 105: , 2005.
2 Chapter 3-58 Abstract Conventional treatment for nasopharyngeal carcinoma (NPC) frequently fails, and is accompanied by severe long-term side effects. Since virtually all undifferentiated NPCs are associated with Epstein Barr virus (EBV), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated viral antigens. We now demonstrate that EBV-specific cytotoxic T-cell lines (CTL) can readily be generated from individuals with NPC, notwithstanding the patients prior exposure to chemotherapy/radiation. Ten patients diagnosed with advanced NPC were treated with autologous CTL. All patients tolerated the CTL, although one developed increased swelling at the site of pre-existing disease. Four patients treated in remission from locally advanced disease remain disease free 19 to 27 months after infusion. Of 6 patients with refractory disease prior to treatment, 2 had complete responses, and remain in remission > months after treatment, 1 had a partial remission that persisted for 12 months, 1 has had stable disease for > 14 months and 2 had no response. These results demonstrate that administration of EBV-specific CTL to patients with advanced NPC is feasible, appears to be safe and can be associated with significant antitumor activity.
3 Introduction Nasopharyngeal carcinoma (NPC) occurs worldwide and is the third most common malignancy in Southern China, where the incidence is as high as 50 per 100, NPC is a radiosensitive tumor and local control rates of greater than 80% can be obtained. However, a significant number of patients relapse, particularly when disease is advanced at diagnosis - the commonest presentation due to a lack of early symptoms. 2 Moreover, radiation and chemotherapy are accompanied by severe short and long-term side effects including secondary malignancies. 3 Hence there is a need for therapies that will improve disease-free survival and that may be associated with reduced toxicity. Chapter 3-59 Epstein Barr Virus (EBV) is present in virtually all poorly and undifferentiated non-keratininzing NPCs regardless of geographical origin 4 and the viral antigens expressed by the tumor provide potential target antigens for immunotherapy. Adoptive transfer of cytotoxic T-cells (CTL) specific for EBV antigens has proven safe and effective as prophylaxis and treatment for EBV associated lymphoproliferative disease in bone marrow and solid organ transplant recipients These highly immunogenic lymphomas express all latent EBV antigens, including the immunodominant EBNA3 antigens, and are therefore ideal targets for immunotherapy. By contrast, NPC expresses a restricted set of less immunogenic viral antigens, namely EBNA1, LMP1 and LMP2. EBNA1 is expressed in all NPCs and although its processing through the HLA class I pathway is inhibited by a glycine-alanine repeat, peptides derived from incompletely translated proteins may be presented to CD8+ T-cells Expression of LMP1 and/or LMP2 is detectable in at least 50% of NPC tumors. 16,17 Since NPCs also express MHC class I molecules as well as the peptide transporters TAP1 and TAP2, they are capable of processing and presenting these antigens in the context of HLA class I molecules for recognition by CTL. 18 LMP1 and LMP2 specific T-cells are indeed present in the peripheral blood of NPC patients, albeit at lower frequency than in normal donors, 19,20 and could potentially be activated and expanded for immunotherapeutic strategies. We hypothesized that ex vivo expansion of EBV-specific CTL in the absence of tumor inhibitory factors 21,22 and the subsequent adoptive transfer of these cells may be of benefit to patients with EBV-positive NPC. Here we confirm the feasibility of this approach, and in 10 patients show evidence for safety and activity.
4 Chapter 3-60 Patients, material and methods Study entry criteria and patient details This protocol was approved by the institutional review board at Baylor College of Medicine and the Food and Drug Administration. Patients were eligible for study if they had stage III or IV nasopharyngeal carcinoma at diagnosis (according to American Joint Committee for Cancer Staging and End-Results Reporting staging system ) and were either in remission or had refractory or relapsed disease, and if their tumor was EBV-positive as determined by in situ hybridization or PCR-amplification for Epstein Barr Virus-Encoded RNA (EBER). Patients were treated on 3 escalating dose levels and received either 2 doses of 2x10 7 CTL/m 2 (dose level 1), or one dose of 2x10 7 CTL/m 2 and 1 dose of 1x10 8 CTL/m 2 (dose level 2) or 1 dose of 1x10 8 CTL/m 2 and 1 dose of 2x10 8 /m 2 (dose level 3). CTL were given intravenously with a 2-week interval between each dose. Peripheral blood was obtained pre and at multiple time points post CTL infusion for evaluation of toxicity and EBV-immunity. Generation of EBV-transformed B cell lines and EBV-specific CTL After informed consent, peripheral blood (40-60 ml) from patients with EBV-positive NPC was used to generate both EBV-transformed lymphoblastoid B-cell lines (LCL) and EBVspecific CTL lines. 24 Briefly, for LCL generation, 5x10 6 peripheral blood mononuclear cells (PBMC) were incubated with concentrated supernatant of B95-8 cultures, in the presence of 1 μg/ml cyclosporin A (Sandoz, Vienna, Austria) to establish an LCL. Subsequently, PBMC (2 x 10 6 per well of a 24 well plate) were stimulated with LCL irradiated at 4000 rads at an effector: stimulator ratio of 40:1. After 9-12 days, viable cells were restimulated with irradiated LCL (at 4:1 E:S ratio). Subsequently, CTL were expanded by weekly stimulations with LCL (at 4:1 E:S ratio) in the presence of recombinant human interleukin-2 (rhil-2, Proleukin, Chiron Corporation, Emeryville, CA) ( U/ml). After expansion, CTLs were tested for sterility, HLA identity, immunophenotype, and EBV specificity and cryopreserved. Specificity was tested in a 4-hour Cr 51 release assay. In 8 lines, the CTL showed a significantly higher killing of the autologous LCLs (mean 56.6%: range 38-92%) as compared to HLA antigen mismatched LCLs (mean 6.1%, range 0-27%, p<0.0001) or to HSB-2 (mean 21.5%, range 6-55% p<0.005) at an E/T ratio of 20:1. In two CTL lines, lysis of the HLA-mismatched LCL was observed, which was significantly reduced by depletion of TCRγδ-positive cells. Auto-reactivity was excluded by the absence of lysis of autologous Phytohemagglutinin (PHA)-stimulated lymphoblasts in all 10 CTL lines. Peptides The following peptides were used for analysis of EBV-specific T-cell populations according to the patients HLA specificity: LMP1: HLA-A2: YLQQNWWTL, YLLEMLWRL, LMP2: HLA- A2: LLWTLVVLL, CLGGLLTMV, FLYALALLI, GLGTLGAAI, TVCGGIMFL, LTAGFLIFL, LIVDAVLQL, HLA-A11: SSCSSCPLSKI, HLA-A24: TYGPVFMCL, HLA-A23/24: PYLFWLAAI, HLA-A68: FTASVSTVV, ASCFTASVSTVVTAT (15-mer), HLA-B27: RRRWRRLTV, RRWRRLTVCGGIMFL (15-mer), RRLTVCGGIMFL, HLA-B60: IEDPPFNSL, EBNA1: HLA-B35: HPVGEADYFEY, EBNA2: HLA-A2: DTPLIPLTIF, EBNA3: HLA-A2: LLDFVRFMGV, HLA-A3: RLRAEAQVK, HLA-A11: AVFDRKSDAK, IVTDFSVIK, LPGPQVTAVLLHHEES, DEPASTEPVHDQLL, NPTQAPVIQLVHAVY, HLA-A24: RYSIFFDY, TYSAGIVQI, HLA-B7: RPPIFIRLL, QPRAPIRPI, HLA-B27: RRIYDLIEL, HLA-B35: YPLHEQHGM, AVLLHEESM, HLAB44: VEITPYKPTW, EGGVGWRHW, EENLLDFVRF, KEHVIQNAF, BZLF1: HLA-B35:
5 EPLPQGQLTAY, BRLF1: HLA-A2: YVLDHLIVV, HLA-A11: ATIGTAMYK, HLA-A24: DYCNVLNKEF, BMLF1: HLA-A2: GLCTLVAML, BMRF1: HLA-A2: TLDYKPLSV (listed in Khanna et al 25 and Houssaint et al 26, and Straathof et al, manuscript in preparation). HLA-A2- restricted Cytomegalovirus pp65-derived peptide NLVPMVATV was used as a control. Peptides were either synthesized by Martin Campbell, Synthetic Antigen Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, or Genemed Synthesis Inc. (South San Francisco, CA). In this paper the peptides are referred to by the first 3 amino acids as underlined. Chapter 3-61 Tetramer staining To identify LMP1 and LMP2-specific T-cells a selection from the following tetramers was used, as determined by the HLA-type of the patient: LMP1: HLA-A*0201-YLQQNWWTL, and LMP2: HLA-A*0201-CLGGLLTMV, HLA-A*0201-FLYALALLI, HLA-A*0201-LLWTLVVLL, HLA-A*0201- TVCGGIMFL, HLA-A*1101-SSCSSCPLSKI, HLA-A*2301-PYLFWLAAI, HLA-A24- TYGPVFMCL, HLA-A68-FTASVSTVV, HLA-B*2705-RRRWRRLTV, and HLA-B*2705- RRLTVCGGIMF. Tetramers were prepared by the National Institute of Allergy and Infectious Diseases (NIAID) tetramer core facility (Atlanta, GA), or by the Baylor College of Medicine Tetramer Core Facility (Houston, TX). CTLs or PBMCs (5-10x10 5 ) were incubated at RT for 30 minutes in PBS/1% FCS containing the PE-labeled tetrameric complex. Samples were costained with anti-cd8 FITC and anti-cd3 PerCP. Appropriate isotype controls were included. Stained cells were fixed in PBS containing 0.5% paraformaldehyde. For each sample, a minimum of 100,000 cells was analyzed using a FACS Calibur with the Cell Quest Software (Becton Dickinson). Enzyme-Linked Immunospot (ELISPOT) assay The frequency of EBV- and LMP2-specific T-cells in the infusion product as well as in the peripheral blood pre and at multiple time points post CTL infusion was measured using an IFN-γ ELISPOT assay. 96-well filtration plates (MultiScreen, #MAHAS4510, Millipore, Bedford, MA) were coated overnight with 10 μg/ml anti-ifn-γ antibody (Catcher-mAB91-DIK, Mabtech, Cincinnati, OH). PBMC were thawed 24 hours before the assay in complete media supplemented with 50 U/ml Benzonase (Novagen, Madison, WI), rested overnight in complete media, and plated at 1-2x10 5 cells/well and 2-3 serial dilutions for LCL targets and 3-4x10 5 /well for peptide targets. CTL were rested overnight in complete media and plated at 1x10 5 cells/well and 2 serial dilutions. Cells were stimulated with either irradiated (40 Gy) autologous LCL (1x10 5 /well) or 5 μg/ml peptide. In HLA-A2-positive patients the Cytomegalovirus (CMV)-pp65 encoded HLA-A2 restricted peptide NLVPMVATV was used as control. After hours, the plates were washed and incubated with the secondary biotin conjugated anti-ifn-γ monoclonal antibody (Detector-mAB (7-B6-1-Biotin), Mabtech). After incubation with Avidin:biotinylated horseradish peroxidase complex (Vectastain Elite ABC Kit (Standard), #PK6100, Vector Laboratories, Burlingame, CA) plates were developed with AEC substrate (Sigma, St. Louis, MO). Plates were sent for evaluation to Zellnet Consulting, New York, NY. Spot-forming units (SFC) per 1x10 5 CTL or per 1x10 6 PBMC were calculated by linear regression analysis when serial dilutions were performed and subsequent subtraction of background of non-stimulated T-cells. If an epitope-specific T-cell population had been identified in the infusion product, EBVand LMP2-specific immunity was monitored in patient peripheral blood using this IFN-γ ELISPOT assay and, when enough PBMC were available and HLA type was informative, by tetramer staining.
6 Chapter 3-62 PCR for EBV-load in PBMC PBMC were isolated from peripheral blood on a Ficoll (Lymphoprep, Axis-Shield, Oslo, Norway) gradient and washed with PBS. DNA was isolated from 3-5x10 6 PBMC using an anion exchange column (Qiagen, Valencia, CA). Five hundred nanograms of DNA was then used for real time polymerase chain reaction (PCR) to quantitate EBV genome copy number and was reported as copies (cp)/μg DNA. 27
7 Results Patient characteristics Ten patients were enrolled on the study and all had poorly differentiated or undifferentiated nasopharyngeal carcinoma (WHO II/III) at diagnosis. Four patients at high risk for relapse were in remission at the time of CTL infusion and six patients had failed multiple rounds of radiotherapy and chemotherapy and had relapsed/refractory disease. Patient characteristics and previous treatment are summarized in Table 1. Chapter 3-63 Table 1. Characteristics of patients on study Patient no. Dose Sex/age HLA Ethnicity Stage Previous treatment Treated in remission x 10 7 /m 2 x 2 M/50 A2/11 B56/ x 10 7 /m 2 x 2 F/29 A2/2 B60/ x 10 7 /m 2 x 2 F/11 A1/2 B37/ x 10 8 /m 2 x 1, 2 x 10 8 /m 2 x 1 Treated with relapsed or refactory disease M/19 A33/36 B53/ x 10 7 /m 2 x 1 M/11 A3/68 B7/ x 10 7 /m 2 x 1, 1 x 10 8 /m 2 x x 10 7 /m 2 x 1, 1 x 10 8 /m 2 x 1* x 10 7 /m 2 x 1, 1 x 10 8 /m 2 x x 10 8 /m 2 x 1, 2 x 10 8 /m 2 x x 10 8 /m 2 x 1, 2 x 10 8 /m 2 x 1 M/36 A1/32 B27/35 F/17 A2/3 B44 M/16 A11/68 B49/52 F/46 A2/24 B51/61 M/16 A30/68 B18/42 Asian IV RT, cisplantin, 5-FU White IV RT, cisplantin, 5-FU African American African American III IV RT, cisplantin, MTX, 5-FU RT, cisplantin, MTX, 5-FU White IV RT, cisplantin, MTX, 5-FU, paclitaxel, carboplantin, VP16, vinorelbine, gemcitabine White III RT, cisplantin, 5-FU, carboplantin, ifospamide, paclitaxel, radioactive seed implants, gemcitabine White IV RT, cisplantin, MTX, 5-FU, carboplantin, paclitaxel Hispanic IV RT, cisplantin, MTX, 5-FU Asian IV RT, cisplantin, 5-FU, docetaxel, CPT-11 African American IV RT, cisplantin, MTX, 5-FU, docetaxel, oxaliplantin, epirubicin, gemcitabine, etoposide M = male, F = Female, RT = radiotherapy, MTX = Methotrexate, 5-FU = 5-Fluoruracil. Stage according to American Joint Committee for Cancer Staging and End-Results Reporting staging system * = this patients received additional doses of 1x10 8 CTL/m 2 at 6 months, 9 months and 12 months after the initial CTL infusions
8 Chapter 3-64 CTL lines contain LMP2-specific T-cell populations Autologous LCL and EBV-specific CTLs were successfully generated from 10 of 10 NPC patients. The phenotype of these CTL lines is shown in Table 2. The presence of LMP1 and LMP2-specific T-cells within these CTL lines was evaluated by IFN-γ ELISPOT after stimulation with LMP1/2-peptides. In 8 of 9 CTL lines for which informative peptides were available based on HLA type, T-cells specific for at least 1 LMP2 epitope were detected (Table 3). In addition, in 1 out of 5 CTL lines evaluable for LMP1-specificity an LMP1-YLL-specific T-cell population was identified. As measured by tetramer staining, up to 5.5% of the total CD8+ population was specific for a single LMP2 epitope (data not shown). In 4 lines, T-cells specific for multiple (up to 5) different LMP2 epitopes were present, in 2 cases these were restricted through different HLA alleles. Such T-cell responses targeted towards multiple tumor antigen-derived epitopes are important to reduce the risk of tumor escape through antigen deletion. Overall the T-cell responses against these subdominant LMP-antigens were weaker than those against epitopes derived from the immunodominant lytic and EBNA3 latent antigens (Table 3), but in the same range as detected in LCL-reactivated CTL lines from healthy donors. 28 Moreover, the identified T-cell populations specific for individual peptides reflect the minimum LMP2-specificity present and likely underestimate the total number of LMP2- specific T-cells. Table 2. Phenotype of patient CTL lines for infusion Patient no. CD3 +/ TCRαβ +,% CD3 +/ TCRγδ +,% CD3 +/ CD4 +,% CD3 +/ CD4 +,% CD3 +/ CD56 +,% CD3 -/ CD56 +,% CD3 -/ CD16 +,% , , ,9 0.0 Safety of EBV-specific CTL Upon administration of EBV-specific CTL no immediate or long-term toxicity was observed in the 4 patients without detectable disease and in 5 out of 6 patients with refractory/relapsed disease (Table 4). However, in one patient (P845) with bulky disease, pre-existing facial swelling increased markedly two days after infusion of the first dose of CTL (2x10 7 /m 2 ) requiring a tracheostomy. A needle biopsy of this mass showed tumor cells and no inflammatory cells suggesting tumor progression as the causative factor, but a contributory effect from CTL cannot be excluded.
9 Table 3. T-cell populations specific for EBV antigens (SFC/1x10 5 CTLs) in infusion product Patient no. LMP1 LMP2 EBNA1 EBNA2/3 Lytic cycle 729 YLQ: 0 CLG: 0 ND DTP: 0 TDL: 3.5 YLL: 0 GLG: 0 LLD: 0 YVL: 31 FLY: 1988 AVF: 0 GLC: 1236 LLW: 0 IVT: 0 ATI: 0 LTA: 0 NPT: 0 TVC: 0 LGP: 0 LIV: 0 DEP: 0 IED: YLQ: 0 CLG: 45 ND DTP: 24 TDL: 50 YLL: 30 GLG: 0 LLD: 0 YVL: 45 FLY: 6 GLC: 1824 LLW: 0 LTA: 0 TVC: 82 LIV: 750 IED: YLQ: 0 CLG: 33 ND DTP: 0 TDL: 12 YLL: 0 GLG: 0 LLD: 256 YVL: 60 FLY: 156 VEI: 0 GLC: 480 LLW: 4 EGG: 96 LTA: 0 KEH: 0 TVC: 0 EEN: 3 LIV: ND FTA: 0 HPV: 0 RPP: 125 EPL: 0 QPR: 0 RLR: 0 YPL: 0 AVL: ND RRR: 3 HVP: 0 RRI: 160 EPL: 1124 RRL: 52 YPL: 26 AVL: YLQ: 0 CLG: 26 ND DTP: 0 TDL: 4 YLL: 0 GLG: 0 LLD: 0 YVL: 7 FLY: 0 VEI: 0 GLC: 934 LLW: 0 EGG: 398 LTA: 0 KEH: 0 TVC: 0 EEN: 506 LIV: 0 RLR: ND SSC: 8 ND AVF: 1214 ATI: 0 FTA: 0 IVT: 1420 NPT: 0 LPG: 0 DEP: YLQ: 0 CLG: 0 ND DTP: 0 DYC: 0 YLL: 0 GLG: 0 LLD: 0 TDL: 0 FLY: 0 RYS: 0 YVL: 0 LLW: 0 TYS: 0 GLC: 0 LTA: 0 TVC: 317 LIV: 0 PYL: 0 TYG: ND FTA: 29 ND ND ND Chapter 3-65 CTL lines were screened for the presence of T-cell populations specific for the indicated antigens by IFN-γ ELISPOT. The panel of peptides used for stimulation was based on the HLA type of the patient (see: Table 1). The sequence of the peptides referred to by the first 3 amino acids is listed in the Methods section. ND = not done as no informative peptides available.
10 Chapter 3-66 Changes in EBV immunity after CTL administration Viral load and the frequency of EBV-specific T-cells were monitored in the peripheral blood at multiple time points post CTL infusion to evaluate persistence and activity of the infused CTL. Of 9 patients with a detectable amount of EBV-DNA in PBMC prior to CTL infusion, EBV load fell within 6 weeks post infusion in 6 patients (Table 5). A decrease in EBV viral load in the peripheral blood likely reflects the lysis of EBV-infected B-cells, and therefore demonstrates activity of the infused EBV-specific CTLs. In 9 of 10 patients the low normal frequency of EBV-specific T-cells in the peripheral blood (mean: 274, range: SFC/1x10 5 PBMC), as measured by IFN-γ secretion of PBMC upon stimulation with autologous LCL, remained unchanged post CTL infusion (data not shown). In one patient (P845) with a low number of circulating EBV-specific CTL prior to CTL infusion (24 SFC/1x10 5 PBMC) a transient 3-fold increase in the number of EBV-specific CTL was measured. In addition, the LMP2-specific T-cell populations identified in the infusion product were monitored in the peripheral blood post CTL infusion. In 5 HLA-A2+ patients, using IFN-γ ELISPOT analysis, the number of T-cells specific for a Cytomegalovirus pp65-derived epitope was determined at the same time points to control for natural variations in viral immunity. In 4 of 8 evaluated patients the number of T-cells specific for LMP2 epitopes increased > 2-fold whereas the pp65-specific immunity remained stable over this time period (Table 5). However, this increase in LMP2-immunity was transient as the number of LMP2-specific T-cells was similar to baseline 6 weeks after CTL infusion in 3 of these 4 patients. Additional tetramer analysis of the frequency of LMP2-specific T-cells in the peripheral blood after CTL infusion in 3 patients failed to detect a persistent increase in LMP2-immunity (data not shown). Clinical responses post CTL therapy indicate anti-tumor activity Clinical responses were evaluated from CT and MRI scans pre and post CTL therapy, using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee. 29 All 4 patients who were in remission at the time of enrollment on the study remain in complete remission months post CTL therapy (Table 4). Of the 6 patients with refractory/relapsed disease, two patients had no response, 1 patient has stable disease for > 14 months without additional therapy, 1 patient had a partial response sustained for 12 months and 2 patients attained complete remission (CR). One of the patients who attained CR (P389) with refractory relapsed disease had a 24% reduction in tumor size after the initial 2 CTL infusions on dose level 2. Because of this partial response, this patient received 3 additional doses of 1x10 8 CTL/m 2 at 6 months, 9 months and 12 months after the initial CTL infusions with IRB and FDA approval. During this period the patient did not receive other Figure 1. Absence of NPC tumor cells in nasopharynx post treatment Biopsies taken pre (left) and post (right, representative of 7 biopsies) the administration of EBV-specific CTL as adjuvant treatment in a patient with refractory NPC (P894) were analyzed for the presence of EBVpositive tumor cells by in situ hybridization for EBER 1 (EBV-encoded small nuclear RNA). EBER-positive cells stain red-brown. The absence of EBER-positive cells post treatment demonstrates a complete response. Full colour image available at: full/105/5/1898 Before After
11 Table 4. Toxicity and clinical responses after CTL therapy Patient no. Toxicity Clinical response Outcome Treated in remission 729 None N/A Remains in remission > 27 mo 606 None N/A Remains in remission > 26 mo 697 None N/A Remains in remission > 25 mo 815 None N/A Remains in remission > 19 mo Treated with relapsed or refactory disease 845 Swelling at tumor site No response then PR after chemotherapy PR for 4 months then progressed and died at 12 mo 894 None CR Remains in remission > 23 mo afther CTLs 389 None CR Remains in remission > 11 mo afther CTLs 918 None PR PR for 12 mo after CTLs then relapsed 1042 None Stable disease Stable disease for > 14 mo 1046 None No response Died of disease at 3 mo Chapter 3-67 N/A = not applicable, CR = complete remission, PR = partial response according to the international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee. 29 Table 5. Virological and immunological response to CTL infusion EBV load (cp/μg DNA) in PBMCs LMP2-specific T cells (SFCs/1x10 6 PBMCs) pp65-specific (SFCs/1x10 6 PBMCs) Patient no. Before 2 wk after 6 wk after Epitope tested Before 2 wk after 6 wk after Epitope tested Before 2 wk after 6 wk after FLY (a) NLV (a) IED NLV LIV 4 ND FLY NLV ND ND ND ND RRL (c) (b) ND CLG NLV SSC ND TVC NLV FTA (c) ND wk = weeks, cp = copies, (a) = 3 months post CTL, (b) = 8 weeks post CTL, as not sufficient number of PBMC available at 6 weeks post CTL time point, (c) = pentadecamers containing minimum epitope were used for stimulation. ND = not done as not enough PBMC or no informative peptide available.
12 Chapter 3-68 treatment and showed continuing response. PET Imaging at 15 months after the first CTL infusion showed normal isotope uptake consistent with a complete response and residual fibrosis. In the second patient who had a CR (P894) a biopsy of the nasopharynx prior to CTL infusion showed poorly differentiated EBER-positive NPC. Multiple biopsies taken 6 months post CTL therapy were all negative for tumor indicating a complete remission (Figure 1). Of the two patients who had no direct response to CTL infusion, one (P845), came off study at 2 weeks because of progressive disease, but subsequently developed a partial response to palliative chemotherapy (Gemcitabine and Carboplatin) to which the disease had been previously unresponsive. The condition of this patient remained stable for 4 months until the tumor again progressed.
13 Discussion Although patients with advanced, relapsed NPC have been exposed to intensive radiation and chemotherapy, EBV-specific CTL can readily be reactivated from their PBMC. Adoptive transfer of these CTL lines appears safe in this patient group, although caution may be required in patients with bulky disease. The infused lines contained cytotoxic T-cells specific for LMP2 (an EBV antigen usually expressed by NPC tumor cells), and were biologically active, reducing levels of EBV DNA in peripheral blood mononuclear cells. Although there was no persistent rise in the frequency of circulating T-cells specific for LMP2 after infusion, the CTL appeared to have significant anti-tumor activity. Two of six patients with disease that was resistant to, or had relapsed after, intensive chemotherapy and radiation, have had complete and sustained remissions. A third patient had a partial response and a fourth has stable disease. All 4 patients who were in remission at the time of CTL infusion remained disease free after months. Chapter 3-69 The EBV-specific CTL used in this study were reactivated using LCL that express all EBV latent antigens. LCL are excellent antigen presenting cells that are readily available for all patients as only a limited amount of blood is required to establish an LCL line. As expected using this method only a minority of the expanded T-cells were specific for the subdominant antigen LMP2. However, upon encounter with NPC cells in vivo these LMP2 specific T-cells may expand in number. Although such an increase in the frequency of LMP2-specific T-cells was not detectable in the peripheral blood in the majority of patients using ELISPOT assays or tetramers, only a small number of T-cells were infused (4-30x10 7 CTL/m 2 ) and less than 10% were LMP2 specific. An expansion of several logs would be required to detect a significant increase in the peripheral blood, and it may be that the infused T-cells instead accumulate and expand at local sites of tumor antigen presentation rather than circulate in the periphery. In addition to LMP2-directed immune responses, immunity to other EBV antigens may have contributed to these tumor responses. Recent insights in the processing and presentation of EBNA1 suggest that although a glycine-alanine repeat prevents the processing of the full-length protein, peptides derived from incompletely translated proteins may be available for T-cell recognition Of note, the CTL line from P894, who attained a complete response, contains a relatively large T-cell population specific for an EBNA1-derived, HLA class I-restricted epitope (Table 3). In addition, clinically relevant doses of chemotherapy can induce the expression of EBV lytic cycle antigens in NPC tumors. 30 Similarly, gamma-irradiation at clinically relevant doses can induce lytic EBV infection in EBV-positive B-cell tumors. 31 Patient 845, who progressed 2 days after CTL therapy, received chemotherapy shortly after CTLs. These chemotherapeutic agents had no anti-tumor effect at an earlier stage, whereas when combined with CTL a partial tumor response was induced. This might be the result of chemotherapy-induced expression of lytic EBV antigens and thus sensitization of the tumor for lytic antigen specific T-cells present in the CTL lines and would provide a rationale for combination of CTL therapy with chemotherapy and/or radiation to enhance CTL efficacy. Previous efforts have been made to recruit the immune system to destroy EBV-positive NPC cells in vivo. Adoptive transfer of similar quantities of autologous EBV-specific CTL as used in this study induced anti-viral responses but no clinical responses in 4 NPC patients treated on a pilot study in China. 32 This lack of tumor response may be explained by the fact
14 Chapter 3-70 that these patients all had end-stage disease with a large tumor burden. Adoptive transfer of an allogeneic EBV-specific CTL line, in one patient with relapsed NPC resulted in a temporary stabilization of disease. 33 Vaccination with dendritic cells loaded with LMP2 peptides induced or boosted LMP2-specific CD8+ T-cell responses in 75% of the patients with advanced stage NPC. 34 In 2 of these patients in whom the LMP2-directed immune response was sustained for 3 months a partial tumor response was induced. How may the success rate of immunotherapy for NPC be increased? The CTL we transfer may undergo only limited in vivo expansion, so that strategies aimed at increasing the number of LMP1 and LMP2 specific T-cell in the infusion product may be of value. We are currently using dendritic cells and/or LCL that over express these subdominant antigens to produce order of magnitude increments in the proportion of cells in CTL lines specific for the EBV latency antigens that are expressed by the tumor. 35,36 In addition, anti-tumor activity after CTL infusion may be augmented by vaccinating patients with an LMP1 polyepitope adenovirus vaccine, 37 LMP2 peptide-loaded dendritic cells 34 or EBNA1-LMP2 transduced dendritic cells. 38 Finally, depletion of the patients endogenous T-cells may promote the expansion of the subsequently infused CTL, a strategy that has been successfully explored by Dudley et al., 39 and which may underlie the greatly increased expansion of infused T-cells after hemopoietic stem cell transplantation. 7,40 Given the feasibility and apparent safety of preparing and administering EBV-specific CTL to patients with advanced NPC, it will be of interest to discover if these and other manipulations further increase the tumor response rate.
15 Reference list 1 Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002;13: Mould RF, Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol. 2002;75: Wang CC, Chen ML, Hsu KH et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with Epstein-Barr virus. Int J Cancer. 2000;87: Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 2000;53: Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10: Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2: Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330: Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T-cells. Blood. 2000;95: Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virusspecific cytotoxic T-cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96: Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99: Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375: Voo KS, Fu T, Wang HY et al. Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes. J Exp Med. 2004;199: Lee SP, Brooks JM, Al Jarrah H et al. CD8 T-cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med. 2004;199: Tellam J, Connolly G, Green KJ et al. Endogenous Presentation of CD8+ T-cell Epitopes from Epstein-Barr Virus-encoded Nuclear Antigen 1. J Exp Med. 2004;199: Niedobitek G, Young LS, Sam CK et al. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol. 1992;140: Heussinger N, Buttner M, Ott G et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol. 2004;203: Khanna R, Busson P, Burrows SR et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 1998;58: Chapter 3-71
16 Chapter Lee SP, Chan AT, Cheung ST et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen- processing function of the tumor cells. J Immunol. 2000;165: Whitney BM, Chan AT, Rickinson AB et al. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol. 2002;67: Oudejans JJ, Harijadi H, Kummer JA et al. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol. 2002;198: Budiani DR, Hutahaean S, Haryana SM, Soesatyo MH, Sosroseno W. Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Microbiol Immunol Infect. 2002;35: American Joint Committee on Cancer (AJCC). Manual for staging of cancer. [5th edition] Lippincott, Philadelphia. 24 Smith CA, Ng CYC, Heslop HE et al. Production of genetically modified EBV-specific cytotoxic T-cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4: Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000;54: Houssaint E, Saulquin X, Scotet E, Bonneville M. Immunodominant CD8 T-cell response to Epstein-Barr virus. Biomed Pharmacother. 2001;55: Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103: Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood. 2000;95: James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91: Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 2002;62: Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and : a potential method for treating EBV-positive malignancies. Cancer Res. 2000;60: Chua D, Huang J, Zheng B et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T-cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94: Comoli P, De Palma R, Siena S et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004;15: Lin CL, Lo WF, Lee TH et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002;62: Bollard CM, Straathof KC, Huls MH et al. The Generation and Characterization of LMP2- Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease. J Immunother. 2004;27:
17 36 Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein- Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101: Duraiswamy J, Bharadwaj M, Tellam J et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 2004;64: Taylor GS, Haigh TA, Gudgeon NH et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol. 2004;78: Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298: Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13. Chapter 3-73
Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas
Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas CM. Bollard, G Dotti, S Gottschalk, E Liu, A Sheehan, M Mims, H Liu, AP. Gee,
More informationEBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham
EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationTranslating EBV Immunology from Bench to Bedside: Somnium Animadverto A Dream Realized
Translating EBV Immunology from Bench to Bedside: Somnium Animadverto A Dream Realized Epstein-Barr Virus Human herpesvirus 90% population infected Associated with many other cancers latent infection.persists
More informationDecreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated
Decreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated nasopharyngeal carcinoma Mark H. Fogg a, Lori J. Wirth b, Marshall Posner b, and Fred Wang a,1 a Department of Medicine,
More informationNovel Approach to the Formulation of an Epstein-Barr Virus Antigen-Based Nasopharyngeal Carcinoma Vaccine
JOURNAL OF VIROLOGY, Jan. 2010, p. 407 417 Vol. 84, No. 1 0022-538X/10/$12.00 doi:10.1128/jvi.01303-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Novel Approach to the Formulation
More informationNumber of Patients Susceptibility Reference HLA-A* (278 EBV+) Increased incidence of. [1] EBV + chl 516 (192 EBV+) Increased incidence of
Supporting Information: Table S1. Previously published HLA-class I associations with. Number of Patients Susceptibility Reference HLA-A*01 934 (278 EBV+) Increased incidence of [1] 516 (192 EBV+) Increased
More informationNIH Public Access Author Manuscript Cytotherapy. Author manuscript; available in PMC 2012 May 1.
NIH Public Access Author Manuscript Published in final edited form as: Cytotherapy. 2011 May ; 13(5): 518 522. doi:10.3109/14653249.2011.561983. Manufacture of GMP-grade Cytotoxic T Lymphocytes specific
More informationSupplemental Table 1. CD8 + and CD4 + T cell epitopes identified in EBV lytic and latent cycle proteins. CD8 + T cell epitopes.
Supplemental Table 1. CD8 + and CD4 + T cell epitopes identified in EBV lytic and latent cycle proteins. CD8 + T cell epitopes EBV Antigen Epitope Coordinates Epitope Sequence HLA Restriction References
More informationImmunotherapy in Treating Nasopharyngeal Carcinoma. Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong
Immunotherapy in Treating Nasopharyngeal Carcinoma Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong Disclosure Received honorarium from Merck Sharp & Dohme (MSD)
More informationEvaluation of T Cell Products LMP-specific T cell therapies for Lymphoma
Evaluation of T Cell Products LMP-specific T cell therapies for Lymphoma CM The Long Winding Road to Successful T cell Therapy Tumor specific T cells in the clinic (CAR modified) Multi-virus specific T
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationJefferson Digital Commons
Thomas Jefferson University Jefferson Digital Commons Department of Medical Oncology Faculty Papers Department of Medical Oncology December 2007 In vitro methods for generating highly purified EBV associated
More informationcancers: A new paradigm in personalized medicine
Immunotherapies for virus associated cancers: A new paradigm in personalized medicine Acknowledgements QIMR Corey Smith Leone Beagley Andrea Schuessler Vijayendra Dasari Martina Sherritt Maher Gandhi Katherine
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationCellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative Disease
American Journal of Transplantation 5; 5: 566 572 Blackwell Munksgaard Copyright C Blackwell Munksgaard 4 doi:./j.6-643.4.693.x Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated
More informationUsing Gene Transfer to Retarget Cytotoxic T lymphocytes. Malcolm Brenner
Using Gene Transfer to Retarget Cytotoxic T lymphocytes Malcolm Brenner Epstein Barr Virus Infects >90% population Acute infection is followed by life-long latency Expression of limited array of viral
More informationEBV Infection. > Cellular Immune Response Profiling. > Humoral Immune Response Profiling EBV. ImmunoTools
EBV ImmunoTools Peptide Tools to Study EBV EBV Infection > Cellular Immune Response Profiling Antigen spanning EBV PepMix Peptide Pools PepMix Collection EBV > Humoral Immune Response Profiling EBV RepliTope
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationEBV infection B cells and lymphomagenesis. Sridhar Chaganti
EBV infection B cells and lymphomagenesis Sridhar Chaganti How EBV infects B-cells How viral genes influence the infected B cell Differences and similarities between in vitro and in vivo infection How
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationMAJOR ARTICLE. (See the editorial commentary by Bitan on pages )
MAJOR ARTICLE Management of Epstein-Barr Virus (EBV) Reactivation after Allogeneic Stem Cell Transplantation by Simultaneous Analysis of EBV DNA Load and EBV-Specific T Cell Reconstitution Nicola E. Annels,
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationInduction and Clearance of Latent HIV Infection:
214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,
More informationT lymphocytes targeting native receptors
Cliona M. Rooney Ann M. Leen Juan F. Vera Helen E. Heslop T lymphocytes targeting native receptors Authors address Cliona M. Rooney 1, Ann M. Leen 1, Juan F. Vera 1, Helen E. Heslop 1 1 Center for Cell
More informationA phase I clinical trial of autologous HER2 CMV bispecific CAR T cells for progressive Glioblastoma
A phase I clinical trial of autologous HER2 CMV bispecific CAR T cells for progressive Glioblastoma Nabil Ahmed, Vita Brawley, Oumar Diouf, Amada Corder, Aidin Ashoori, Alexia Ghazi, Claudia Gerken, Joanna
More informationSHORT COMMUNICATION. RAJIV KHANNA,*,2,3 SCOTT R. BURROWS,*,2 PATTY M. STEIGERWALD-MULLEN, SCOTT A. THOMSON,* MICHAEL G. KURILLA, and DENIS J.
VIROLOGY 214, 633 637 (1995) SHORT COMMUNICATION Isolation of Cytotoxic T Lymphocytes from Healthy Seropositive Individuals Specific for Peptide Epitopes from Epstein Barr Virus Nuclear Antigen 1: Implications
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationClinical implications of Epstein-Barr virus strain diversity
Mini Review Open Access Clinical implications of Epstein-Barr virus strain diversity Ana Cirac 1,2,3, Uta Behrends 1,2,3, and Josef Mautner 1,2,3 * 1 Children s Hospital, Technische Universität München,
More informationTherapeutic vaccination strategies to treat nasopharyngeal carcinoma
Review Article Page 1 of 14 Therapeutic vaccination strategies to treat nasopharyngeal carcinoma Graham S. Taylor, Neil M. Steven Cancer Immunology and Immunotherapy Centre, University of Birmingham, Vincent
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. EBV Post Transplantation Implications and Approach to Management
2017 CST-Astellas Canadian Transplant Fellows Symposium EBV Post Transplantation Implications and Approach to Management Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University
More informationMethods additional information. Vaccine manufacture
Therapeutic vaccination of Epstein-Barr Virus (EBV) Malignancies: phase 1 trial of recombinant Modified Vaccinia Ankara encoding EBV-encoded tumour antigens in nasopharyngeal carcinoma patients Methods
More informationHaploidentical Transplantation Helen Heslop
Haploidentical Transplantation Helen Heslop Outline Haplodentical transplantation Indications Regimens Outcomes KIR mismatching and NK cells Reconstituting T cell immunity Allodepleted T cells Cytotoxic
More informationSupplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in
Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationT cell manipulation of the graft: Yes
T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins
More informationCellular & Molecular Immunology 229
Cellular & Molecular Immunology 229 Combined Transfection with EBV-Specific Epitopes and HLA-A2 genes is More Effective than Separate Transfection in Promoting CTL Lysis against Nasopharyngeal Carcinoma
More informationEpstein-Barr virus and immunity
Epstein-Barr virus and immunity Elena Kashuba, PhD Associate Professor Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet 1 Epstein-Barr virus EBV Everybody s virus 200 nm Enveloped
More informationProgressive Telomere Shortening of Epstein-Barr Virus Specific Memory T Cells during HIV Infection: Contributor to Exhaustion?
BRIEF REPORT Progressive Telomere Shortening of Epstein-Barr Virus Specific Memory T Cells during HIV Infection: Contributor to Exhaustion? Debbie van Baarle, 1 Nening M. Nanlohy, 1 Sigrid Otto, 1 Fiona
More informationEBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein
Cellular & Molecular Immunology 269 Article EBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein Yun Chen 1, 2, Hua Sun 3, Genyan Liu 1, 4, Bing Wang 1, Fang
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited
AD (Leave blank) Award Number: W81XWH-07-1-0345 TITLE: Second-Generation Therapeutic DNA Lymphoma Vaccines PRINCIPAL INVESTIGATOR: Larry W. Kwak, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Texas
More informationPublished in final edited form as: Clin Cancer Res October 1; 20(19): doi: / ccr t.
Europe PMC Funders Group Author Manuscript Published in final edited form as: Clin Cancer Res. 2014 October 1; 20(19): 5009 5022. doi:10.1158/1078-0432.ccr-14-1122-t. A recombinant modified vaccinia Ankara
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationCommercially available HLA Class II tetramers (Beckman Coulter) conjugated to
Class II tetramer staining Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to PE were combined with dominant HIV epitopes (DRB1*0101-DRFYKTLRAEQASQEV, DRB1*0301- PEKEVLVWKFDSRLAFHH,
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationImmune surveillance: The immune system can recognize and destroy nascent malignant cells
Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationResults. Clinical reports of transplant recipients
Cloning of EBV genes as fusion proteins with Renilla luciferase for Luciferase Immunoprecipitation System (LIPS) analysis A panel of 13 different EBV proteins was generated as Renilla luciferase (Ruc)
More informationAdoptive Immunotherapy for Posttransplantation Viral Infections
Biology of Blood and Marrow Transplantation 10:143-155 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1003-0001$30.00/0 doi:10.1016/j.bbmt.2003.09.017 Adoptive Immunotherapy
More informationMinor H Antigen-Specific T Cells -The Black Box of the GVL Effect
Minor H Antigen-Specific T Cells -The Black Box of the GVL Effect All Allogeneic Stem Cell Transplants Are Blind Doctor Donor Patient Genetic polymorphism gives rise to unique peptides in donor and recipient
More informationT-cell Therapies for Hematologic Malignancies: Utilizing A Non-Gene Transfer Approach. Catherine Bollard
T-cell Therapies for Hematologic Malignancies: Utilizing A Non-Gene Transfer Approach Catherine Bollard Rationale of Immunotherapy for EBV-positive Lymphoma Significant failure rate of therapy for advanced
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationEpstein-Barr virus (EBV), a linear double-stranded DNA
Epstein-Barr Virus as a Paradigm in Nasopharyngeal Cancer: From Lab to Clinic Radha Raghupathy, MD, Edwin Pun Hui, MD, and Anthony Tak Cheung Chan, MD, FRCP OVERVIEW Nasopharyngeal carcinoma (NPC) of the
More informationTonsillar homing of Epstein-Barr virus specific CD8 + T cells and the virus-host balance
Research article Tonsillar homing of Epstein-Barr virus specific CD8 + T cells and the virus-host balance Andrew D. Hislop, 1 Michael Kuo, 2 Adrian B. Drake-Lee, 2 Arne N. Akbar, 3 Wolfgang Bergler, 4
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationAntiviral Adoptive Immunotherapy for Primary Immunodeficiency Disorders. Speaker Disclosures
3/27/218 Antiviral Adoptive Immunotherapy for Primary Immunodeficiency Disorders Michael Keller, MD Program for Cell Enhancement & Technologies for Immunotherapy (CETI) Director: Dr. Catherine Bollard
More informationHuman Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells
Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Gavin M. Mason, Sarah Jackson, Georgina Okecha, Emma Poole, J. G. Patrick Sissons, John Sinclair,
More informationNanoparticles and persistent virus infection a dangerous liaison for the development of chronic lung disease(s)? Tobias Stöger
Nanoparticles and persistent virus infection a dangerous liaison for the development of chronic lung disease(s)? Tobias Stöger Herpesviruses and lung disease Double-stranded DNA-viruses (a, b, g- herpesviruses)
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationMATERIALS AND METHODS
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10391 10396, August 1999 Medical Sciences Activation and adoptive transfer of Epstein Barr virus-specific cytotoxic T cells in solid organ transplant patients with
More informationstaining and flow cytometry
Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationATA129 for Epstein-Barr virusassociated. lymphoproliferative disorder
March 2017 Horizon Scanning Research & Intelligence Centre ATA129 for Epstein-Barr virusassociated post-transplant lymphoproliferative disorder NIHR HSRIC ID: 10876 Lay summary ATA129 is a new treatment
More informationBroad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation
Editorial Page 1 of 5 Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation Britta Maecker-Kolhoff 1,2, Britta Eiz-Vesper 2,3 1 Department of Pediatric
More informationRecognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E specific CD8 T cell clone
Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (30 June 2006) Vol. 6, p. 9 Submitted: 2 September 2005. Resubmitted: 28 April 2006. Accepted: 2 June 2006. Copyright 2006 by Mayumi Nakagawa
More information0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no
2003 12 10 83 23 Natl Med J China, December 10,2003,Vol 83, No. 23 2049 (CIK ), T, CIK 13 (PBMC),,4 7 10 13 15 ;CIK, (DC1) (CD2),CD3 + CD8 +, CD3 + CD56 +, CD25 +, 3315 % 1011 % 717 % 218 %1213 % 415 %,3616
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationDirect ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central
More informationRapid antigen-specific T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More information